Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
CONCLUSION: The analysis shows that alemtuzumab is a cost-saving alternative to treat RRMS in pretreated and therapy naïve patients. From the patient perspective alemtuzumab improves quality of life.
PMID: 30522373 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Austria Health | Avonex | Betaseron | Disability | Economics | Gilenya | Health Management | Multiple Sclerosis | Rebif | Tysabri